Actinium Announces Positive Top-line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia
Iomab-B met the primary endpoint of durable complete remission of 6-months following initial complete remission after HCT with a p-value of ... Biopharmaceuticals, Oncology Actinium Pharmaceuticals, Iomab-B, targeted radiotherapies, radiotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 31, 2022 Category: Pharmaceuticals Source Type: news

Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment
This final guidance is intended to assist sponsors in the clinical development of drugs and biological products for the treatment of AML. This guidance addresses FDA ’s current thinking regarding the overall development program and clinical trial designs for AML drugs. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 17, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Episode 6: MRD and Relapse in Patients With AML Episode 6: MRD and Relapse in Patients With AML
Drs Gail Roboz and Roland Walter discuss measurable residual disease and relapse in patients with acute myeloid leukemia.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 17, 2022 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news

AML's Seasonal Peak Suggests Viral or Environmental Etiology AML's Seasonal Peak Suggests Viral or Environmental Etiology
The finding that most diagnoses of acute myeloid leukemia are made during January raises the possibility that the cancer results from infectious or environmental agents.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - August 16, 2022 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Is a Cure for HIV Finally within Reach?
By Esther Tumbare, Senior global technical director for HIV A health worker at the San Marcos National Hospital in Guatemala holds an HIV test. Photo by Levi Dieguez for IntraHealth International.July 26, 2022Despite huge strides and years of methodical research, efforts to find a simple, easily scalable HIV cure have evaded the scientific world. An HIV cure includes both remission and eradication and needs to be accessible to the millions of people living with HIV, most of them in Africa.Today we are closer to a cure than we’ve ever been before.In 2008, the first cure in an HIV-infected patient was announced. ...
Source: IntraHealth International - July 26, 2022 Category: International Medicine & Public Health Authors: kseaton Tags: HIV & AIDS Source Type: news

Air Pollution May Increase Risk for Childhood Leukemia
Strongest association seen for benzene exposure and acute myeloid leukemia (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 21, 2022 Category: Cancer & Oncology Tags: Oncology, Pediatrics, Journal, Source Type: news

Episode 5: Treating Older AML Patients and Managing Unique Toxicities Episode 5: Treating Older AML Patients and Managing Unique Toxicities
Drs Gail Roboz and Courtney DiNardo discuss methods of treating older patients with acute myeloid leukemia and managing unique toxicities.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 20, 2022 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news

An Aggressive Leukemia Is More Lethal for Black Patients
New research shows outcomes are worse for Black patients with acute myeloid leukemia (AML) than white patients who received similar intensive therapy on clinical trials. (Source: WebMD Health)
Source: WebMD Health - July 7, 2022 Category: Consumer Health News Source Type: news

'Well he's better now' - Man who survived leukaemia as a teen calls for more understanding
UNDERGOING treatment for cancer is a difficult time for all patients, both physically and mentally. And if the patient is just a teenager it can be challenging for so many other reasons too. That was the case for Rian Harvey, from Dorset, who was only 14 years old when he was diagnosed with acute myeloid leukaemia. (Source: Daily Express - Health)
Source: Daily Express - Health - June 26, 2022 Category: Consumer Health News Source Type: news

Episode 4: Adverse-Risk Acute Myeloid Leukemia Episode 4: Adverse-Risk Acute Myeloid Leukemia
Drs Gail Roboz and Alexander Perl discuss adverse-risk acute myeloid leukemia.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 16, 2022 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news

Similar Survival, Less Toxicity With Decitabine vs Chemo in AML Similar Survival, Less Toxicity With Decitabine vs Chemo in AML
For patients with acute myeloid leukemia, treatment with decitabine prior to stem cell transplantation had similar overall survival and much less toxicity compared with intensive chemotherapy.Medscape Medical News (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - June 12, 2022 Category: Transplant Surgery Tags: Hematology-Oncology News Source Type: news

Roche announces positive data from broad blood cancer portfolio at European Hematology Association Annual Meeting
Long-term data at the European Hematology Association (EHA) 2022 congress expands understanding of the impact of Roche medicines in early-stage blood cancers with the goal of providing patients with robust and durable outcomes from their first treatmentUpdated data from phase III CLL14 study of Venclexta ®/Venclyxto® (venetoclax) plus Gazyva®/Gazyvaro® (obinutuzumab) showed more than 60% of previously untreated people with chronic lymphocytic leukaemia remained in remission five years after starting treatment[1]Final analysis of phase III GALLIUM study showed meaningful improvement in progression-free survival was main...
Source: Roche Investor Update - June 10, 2022 Category: Pharmaceuticals Source Type: news

Roche announces positive data from broad blood cancer portfolio at European Hematology Association Annual Meeting
Long-term data at the European Hematology Association (EHA) 2022 congress expands understanding of the impact of Roche medicines in early-stage blood cancers with the goal of providing patients with robust and durable outcomes from their first treatmentUpdated data from phase III CLL14 study of Venclexta ®/Venclyxto® (venetoclax) plus Gazyva®/Gazyvaro® (obinutuzumab) showed more than 60% of previously untreated people with chronic lymphocytic leukaemia remained in remission five years after starting treatment[1]Final analysis of phase III GALLIUM study showed meaningful improvement in progression-free survival was main...
Source: Roche Media News - June 10, 2022 Category: Pharmaceuticals Source Type: news

Servier Announces FDA Approval of Tibsovo (ivosidenib tablets) in Combination with Azacitidine for Patients with Newly Diagnosed IDH1-mutated Acute Myeloid Leukemia
Tibsovo is the first therapy targeting cancer metabolism approved in combination with azacitidine for patients with newly diagnosed IDH1-mutated acute myeloid leukemia FDA approval based on data from the global, Phase 3 AGILE trial that... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 25, 2022 Category: Drugs & Pharmacology Source Type: news

Episode 3: Intermediate-Risk Acute Myeloid Leukemia Episode 3: Intermediate-Risk Acute Myeloid Leukemia
Drs Gail Roboz and Pinkal Desai discuss intermediate-risk acute myeloid leukemia.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 19, 2022 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news